QQ客服 官方微博 反馈留言

	A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
	Hu, Xingsheng; Wang, Lin; Lin, Lin; Han, Xiaohong; Dou, Guifang; Meng, Zhiyun; Shi, Yuankai
	2016
卷号	28期号:4页码:444-451
关键词	Chidamide HDAC inhibitor phase I paclitaxel and carboplatin non-small cell lung cancer
ISSN号	1000-9604
DOI	10.21147/j.issn.1000-9604.2016.04.08
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ISTIC
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383881
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hu, Xingsheng,Wang, Lin,Lin, Lin,et al. A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer[J],2016,28(4):444-451.
APA	Hu, Xingsheng.,Wang, Lin.,Lin, Lin.,Han, Xiaohong.,Dou, Guifang.,...&Shi, Yuankai.(2016).A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.,28(4),444-451.
MLA	Hu, Xingsheng,et al."A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer".28.4(2016):444-451.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。